A Phase I/II, Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Endometrial Cancer or Squamous NSCLC
Latest Information Update: 08 Aug 2024
At a glance
- Drugs ABTL 0812 (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Endometrial cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Endolung
- Sponsors Ability Pharmaceuticals
- 22 Jul 2024 Results assessing safety and efficacy of Ibrilatazar (ABTL0812) with CP in patients with advanced/recurrent EC and non-irradiable stage III and IV squamous non-small cell lung cancer published in the BMC Cancer
- 06 Jun 2023 Results(n=40) assessing the safety of ABTL0812 in combination with paclitaxel and carboplatin in first-line patients with advanced squamous non-small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 01 Jun 2023 Results presented in the Ability Pharmaceuticals Media Release.